Pfizer (NYSE:PFE) Price Target Raised to $28.00

Pfizer (NYSE:PFE) had its price target hoisted by research analysts at Morgan Stanley from $27.00 to $28.00 in a report released on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price target indicates a potential upside of 3.72% from the company’s previous close.

A number of other research analysts have also weighed in on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. Bank of America decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Thursday. Finally, Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $28.14.

Pfizer Price Performance

Shares of NYSE:PFE traded down $0.23 during trading on Friday, reaching $27.00. 8,192,699 shares of the company’s stock traded hands, compared to its average volume of 44,471,402. Pfizer has a fifty-two week low of $21.28 and a fifty-two week high of $28.75. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The firm has a market cap of $153.50 billion, a PE ratio of 19.86 and a beta of 0.43. The company has a 50-day simple moving average of $27.19 and a 200-day simple moving average of $25.91.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period last year, the firm earned $0.63 EPS. As a group, analysts predict that Pfizer will post 2.95 earnings per share for the current year.

Institutional Trading of Pfizer

Institutional investors have recently added to or reduced their stakes in the stock. Horizon Financial Services LLC increased its holdings in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. purchased a new stake in Pfizer during the fourth quarter worth about $26,000. YANKCOM Partnership acquired a new stake in shares of Pfizer during the fourth quarter worth about $28,000. HFM Investment Advisors LLC lifted its position in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares in the last quarter. Finally, Grey Fox Wealth Advisors LLC purchased a new position in shares of Pfizer in the third quarter valued at approximately $29,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s oncology franchise and pipeline are highlighted as strengths that could support future revenue and margin upside ahead of upcoming quarterly results. How Pfizer’s Oncology Portfolio Is Shaping Up Before Q1 Results
• Positive Sentiment: Analysis arguing Pfizer may still offer value after a strong one‑year share gain, which could attract value-oriented investors if fundamentals remain steady. Is Pfizer (PFE) Offering Value After Its 31% One Year Share Price Jump
• Neutral Sentiment: Pfizer is drawing increased attention from retail and research audiences — a “trending” status that can boost volume/volatility but doesn’t by itself change fundamentals. Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Pfizer announced its virtual 2026 annual meeting (April 23) — routine corporate governance event that provides investor access but is unlikely to move the stock materially. Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
• Neutral Sentiment: Broader industry research (biopharma CXO market forecast) notes outsourcing and supply‑chain trends that affect all large pharmas, including Pfizer — thematic tailwinds for cost/supply strategies but not an immediate stock catalyst. $1.05 Bn Biopharmaceutical CXO Markets – Global Forecast Report 2026-2032
• Negative Sentiment: Competitor AbbVie is outpacing Pfizer in recent growth (Skyrizi/Rinvoq offsetting Humira losses), a dynamic investors see as a competitive headwind for Pfizer’s market share and growth story. Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?
• Negative Sentiment: Bank of America trimmed its price target on PFE (from $27 to $26) and set a neutral rating — a near‑term downgrade that lowers analyst upside and can pressure sentiment. Benzinga coverage of price target cut
• Negative Sentiment: Coverage of recent intraday weakness explains a recent tumble in the stock tied to mixed Q4 comparisons and investor rotation away from large-cap branded pharmas, contributing to short-term selling pressure. Why Pfizer Stock Tumbled on Tuesday

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.